These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39152982)

  • 1. Reprint of: Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis.
    Moore M; Vizcaino K; Ewing JA; St Ville M
    J Am Pharm Assoc (2003); 2024; 64(4S):102160. PubMed ID: 39152982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of apixaban compared to warfarin for nonvalvular atrial fibrillation in end-stage renal disease on hemodialysis.
    Moore M; Vizcaino K; Ewing JA; St Ville M
    J Am Pharm Assoc (2003); 2024; 64(2):457-462. PubMed ID: 38151201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non-valvular atrial fibrillation: protocol for a prospective, randomised, open-label, blinded endpoint trial (APIDP2).
    Ficheux M; Peyro-Saint-Paul L; Balayn D; Lecrux B; Brossier M; Morin A; Lanot A; Peron C; Boulanger M; Brionne M; Beygui F; Parienti JJ; Lobbedez T; Béchade C
    BMJ Open; 2024 Sep; 14(9):e089353. PubMed ID: 39306346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic Hemodialysis.
    Kufel WD; Zayac AS; Lehmann DF; Miller CD
    Pharmacotherapy; 2016 Nov; 36(11):e166-e171. PubMed ID: 27643979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment.
    Jones MJ; Eudaley ST; Moye RA; Hodge TA; Nesbit RM; Franks AS
    J Thromb Thrombolysis; 2020 Aug; 50(2):330-336. PubMed ID: 31902123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial.
    Guimarães PO; Pokorney SD; Lopes RD; Wojdyla DM; Gersh BJ; Giczewska A; Carnicelli A; Lewis BS; Hanna M; Wallentin L; Vinereanu D; Alexander JH; Granger CB
    Clin Cardiol; 2019 May; 42(5):568-571. PubMed ID: 30907005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of oral anticoagulants for stroke prevention in atrial fibrillation using the UK clinical practice research Datalink Aurum: A reference trial (ARISTOTLE) emulation study.
    Powell EM; Gungabissoon U; Tazare J; Smeeth L; Baptiste PJ; Bin Hammad TM; Wong AYS; Douglas IJ; Wing K
    PLoS Med; 2024 Aug; 21(8):e1004377. PubMed ID: 39207948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of Apixaban Versus Warfarin in Obese Patients with Nonvalvular Atrial Fibrillation Enrolled in Medicare and Veteran Affairs.
    Deitelzweig S; Sah J; Kang A; Russ C; Preib M; Dhamane AD; Ratiu A; Cato M; Alfred T; Levi E; Di Fusco M
    Am J Cardiol; 2022 Jan; 163():43-49. PubMed ID: 34930532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
    Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease.
    Schafer JH; Casey AL; Dupre KA; Staubes BA
    Ann Pharmacother; 2018 Nov; 52(11):1078-1084. PubMed ID: 29871510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Major Bleeding, Stroke/Systemic Embolism, and Death Associated With Different Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Chronic Kidney Disease.
    Xu Y; Ballew SH; Chang AR; Inker LA; Grams ME; Shin JI
    J Am Heart Assoc; 2024 Aug; 13(16):e034641. PubMed ID: 39119973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data.
    Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH
    Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apixaban versus No Anticoagulation in Patients Undergoing Long-Term Dialysis with Incident Atrial Fibrillation.
    Mavrakanas TA; Garlo K; Charytan DM
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1146-1154. PubMed ID: 32444398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of Oral Anticoagulation in the Management of Atrial Fibrillation in Patients with ESRD: Pro.
    McCullough PA; Ball T; Cox KM; Assar MD
    Clin J Am Soc Nephrol; 2016 Nov; 11(11):2079-2084. PubMed ID: 27797888
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes Associated With Apixaban Use in Patients With End-Stage Kidney Disease and Atrial Fibrillation in the United States.
    Siontis KC; Zhang X; Eckard A; Bhave N; Schaubel DE; He K; Tilea A; Stack AG; Balkrishnan R; Yao X; Noseworthy PA; Shah ND; Saran R; Nallamothu BK
    Circulation; 2018 Oct; 138(15):1519-1529. PubMed ID: 29954737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study.
    Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A
    J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterizing the Safety Profile of Apixaban Versus Warfarin in Moderate to Severe Chronic Kidney Disease at a Veterans Affairs Hospital.
    Herndon K; Guidry TJ; Wassell K; Elliott W
    Ann Pharmacother; 2020 Jun; 54(6):554-560. PubMed ID: 31872779
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and effectiveness of apixaban in comparison to warfarin in patients with nonvalvular atrial fibrillation: a propensity-matched analysis from Japanese administrative claims data.
    Kohsaka S; Katada J; Saito K; Terayama Y
    Curr Med Res Opin; 2018 Sep; 34(9):1627-1634. PubMed ID: 29772946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.